Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Siga Technologies Inc. (SIGA : NSDQ)

• Company Description    SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. With broad technology platforms in both vaccines and antibiotics, SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses, dengue virus, and the filoviruses. Number of Employees: 46

• Price / Volume Information    Yesterday's Closing Price: $8.92 Daily Weekly Monthly 20 Day Moving Average: 499,153 shares Shares Outstanding: 71.61 (millions) Market Capitalization: $638.73 (millions) Beta: 0.95 52 Week High: $9.62 52 Week Low: $4.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.96% 2.14% 12 Week 38.94% 26.21% Year To Date 48.42% 34.74%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 31 EAST 62ND STREET - NEW YORK,NY 10065 USA ph: 212-672-9100 fax: 212-697-3130 investorrelationsweb@siga.com http://www.siga.com

• General Corporate Information    Officers Diem Nguyen - Chief Executive Officer and Director Daniel J. Luckshire - Executive Vice President and Chief Financial Offic Jaymie Durnan - Director Harold E. Ford - Director Joseph Marshall - Director Peer Information Siga Technologies Inc. (GSAC) Siga Technologies Inc. (CASI) Siga Technologies Inc. (ALCD.) Siga Technologies Inc. (OMNN) Siga Technologies Inc. (CGPI.) Siga Technologies Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 826917106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 71.61 Most Recent Split Date: (:1) Beta: 0.95 Market Capitalization: $638.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 7.89 PEG Ratio: - Price Ratios Price/Book: 3.05 Price/Cash Flow: 10.66 Price / Sales: 3.56 EPS Growth vs. Year Ago Period: 1,533.33% vs. Previous Quarter: 5,000.00% Sales Growth vs. Year Ago Period: 271.92% vs. Previous Quarter: 1,052.11% ROE 06/30/25 - 40.52 03/31/25 - 25.21 12/31/24 - 32.96 ROA 06/30/25 - 35.62 03/31/25 - 22.05 12/31/24 - 27.03 Current Ratio 06/30/25 - 10.09 03/31/25 - 8.40 12/31/24 - 9.12 Quick Ratio 06/30/25 - 8.52 03/31/25 - 6.28 12/31/24 - 7.16 Operating Margin 06/30/25 - 45.73 03/31/25 - 40.30 12/31/24 - 42.66 Net Margin 06/30/25 - 45.73 03/31/25 - 40.30 12/31/24 - 42.66 Pre-Tax Margin 06/30/25 - 59.67 03/31/25 - 51.79 12/31/24 - 54.84 Book Value 06/30/25 - 2.92 03/31/25 - 3.03 12/31/24 - 3.02 Inventory Turnover 06/30/25 - 0.80 03/31/25 - 0.50 12/31/24 - 0.54 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©